Shire plc, the globalspecialty biopharmaceutical company, announced findings from a post hocanalysis examining emotional lability from Phase 3 study data with Vyvanse.In this study, Vyvanse demonstrated significant improvement inAttention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured bythe ADHD Rating Scale IV (ADHD-RS IV) and Connors’ Parent RatingScale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
The post hoc analysis showed that patients demonstrated an improvementin emotional lability composite CPRS-RS scores while taking Vyvanse ascompared to placebo. These results were presented recently at apsychiatric meeting in Honolulu.
“Children taking ADHDmedications can experience emotional lability, often described asfrequent changes in emotions or mood. Therefore, evaluating the impactof ADHD treatments, including Vyvanse, on children’s emotional labilitymay be important for parents and health care professionals whenassessing a child’s treatment plan,” said Ann C Childress, studyinvestigator and president of the Center for Psychiatry and BehavioralMedicine, Inc in Las Vegas.